Epigenetic enzymes control the mechanics of genetic expression, acting as "on" and "off" switches for the human genome. Malfunctions of these enzymes are implicated in a number of cancer, immunological, and neurodegenerative conditions. Understanding these mechanisms can explain why one person with a genetic disposition to a certain type of cancer may become sick while another with the same genetic marker may stay healthy.
The project will consist of taking a library of 1400 compounds, including almost every
Dr. Haiching Ma, Chief Science Officer of RBC and Principal Investigator of the study, said, "This project will represent the first systematic look at how current pharmaceuticals affect epigenetic function. The potential exists for some exciting developments as a result. We're very pleased that NCATS saw the same potential in this project as we did."
Most Popular Stories
- Islamic State Obliterating Cultural Landmarks in Mosul
- The 2014 Fastest-Growing 100
- 'Lucy's' Super Powers Tops 'Hercules' at Box Office
- VW Site Could Mean Another 2,000 Jobs for Chattanooga
- RV Sales See Highest Increase Post Great Recession
- Report: China to Declare Qualcomm a Monopoly
- Eid al-Fitr Celebrations Mark End of Ramadan
- Oppression of Women Cripples Africa: Obama
- Insecticides Permeate U.S. Food, Water Supply
- Anarchy, Chaos Sweep Across Libya